BioSpace News Archive

Kubota Vision Inc., a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., announced positive clinical results from myopia control tests in humans.

Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced that it has received CE Mark for the Edwards PASCAL transcatheter valve repair system for the treatment of European patients with tricuspid regurgitation.

Vifor Fresenius Medical Care Renal Pharma and ChemoCentryx, Inc., announced topline data from a forty-six patient phase-II dose-ranging trial in the orphan kidney disorder, primary Focal Segmental Glomerulosclerosis.

Tumor cells inhibit myeloid cell phagocytosis and dendritic cell antigen presentation through the novel “Don’t eat me” signal mediated by CLEC-1

StageZero Life Sciences announced that it will release its Fourth Quarter 2019 operational results before markets open on Tuesday, May 19, 2020.

The preclinical prototype vaccine is well-tolerated and provides strong protection against coxsackievirus B infections and diabetes in relevant animal models

Data from SER-109 Phase 3 study in recurrent C. difficile infection expected mid-2020

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced additional findings from its Phase II study of Namodenoson in the treatment of patients with non-alcoholic fatty liver disease with or without non-alcoholic steatohepatitis.

bluebird bio, Inc. announced that it has commenced an underwritten public offering of $400 million of its common stock. bluebird bio also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent of the shares of common stock offered in the public offering.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that it has appointed Kenneth Rhodes, PhD, as Senior Vice President, Therapeutics Discovery. In this newly created position, Dr. Rhodes will be responsible for defining the strategy and guiding discovery research to design new therapeutic candidates and adva